Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 71, Issue 9, 2012, Pages 1545-1551

  Gonzalez, Estrella Garcia ^a   Selvi, Enrico ^a   Balistreri, Epifania ^a   Akhmetshina, Alfiya ^b   Palumbo, Katrin ^b   Lorenzini, Sauro ^a   Lazzerini, Pietro Enea ^c   Montilli, Cinzia ^c   Capecchi, Pier Leopoldo ^c   Lucattelli, Monica ^a   Baldi, Caterina ^a   Gianchechi, Elena ^c   Galeazzi, Mauro ^a   Pasini, Franco Laghi ^c   Distler, Jörg H W ^b  

^a Department of Clinical Medicine and Immunological Sciences ^*  (Italy)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Immunology Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AJULEMIC ACID; ALPHA SMOOTH MUSCLE ACTIN; CELL MARKER; COLLAGEN; HYDROXYPROLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFIBROTIC ACTIVITY; ARTICLE; CELL ACTIVATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; FIBROGENESIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SKIN FIBROSIS; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANIMALS; CANNABINOIDS; COLLAGEN; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; MALE; MICE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; TETRAHYDROCANNABINOL;

EID: 84864869606     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200314     Document Type: Article

References (34)

1. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005;5:400-11. (Pubitemid 40685989)
2. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009;156:397-411.
3. Teixeira-Clerc F, Julien B, Grenard P, et al. The endocannabinoid system as a novel target for the treatment of liver fibrosis. Pathol Biol 2008;56:36-8.
4. Michalski CW, Maier M, Erkan M, et al. Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. PLoS One 2008;3:e1701.
5. Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005;168:1-51.
6. Akhmetshina A, Dees C, Busch N, et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 2009;60:1129-36.
7. Marquart S, Zerr P, Akhmetshina A, et al. Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum 2010;62:3467-76.
8. Servettaz A, Kavian N, Nicco C, et al. Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am J Pathol 2010;177:187-96.
9. Balistreri E, Garcia-Gonzalez E, Selvi E, et al. The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model. Ann Rheum Dis 2011;70:695-9.
10. Burstein S. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials. AAPS J 2005;7:E143-8. (Pubitemid 41554292)
11. Salim K, Schneider U, Burstein S, et al. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology 2005;48:1164-71. (Pubitemid 40725989)
12. Vann RE, Cook CD, Martin BR, et al. Cannabimimetic properties of ajulemic acid. J Pharmacol Exp Ther 2007;320:678-86. (Pubitemid 46147948)
13. Karst M. Comments on "cannabimimetic properties of ajulemic acid". J Pharmacol Exp Ther 2007;322:420-1. (Pubitemid 46956387)
14. Liu J, Li H, Burstein SH, et al. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol 2003;63:983-92. (Pubitemid 36529916)
15. Burstein S. PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci 2005;77:1674-84. (Pubitemid 41073661)
16. Sun Y, Alexander SP, Garle MJ, et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol 2007;152:734-43. (Pubitemid 350034991)
17. Giuliano M, Pellerito O, Portanova P, et al. Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma. Biochimie 2009;91:457-65.
18. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007;152:576-82. (Pubitemid 350034977)
19. Wei J, Ghosh AK, Sargent JL, et al. PPARγ downregulation by TGFβ in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010;5:e13778.
20. Genovese T, Cuzzocrea S, Di Paola R, et al. Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur Respir J 2005;25:225-34. (Pubitemid 40246521)
21. Kapoor M, McCann M, Liu S, et al. Loss of peroxisome proliferator- activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 2009;60:2822-9.
22. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67. (Pubitemid 46348510)
23. Beyer C, Schett G, Distler O, et al. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010;62:2831-44.
24. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009;60:219-24.
25. Avouac J, Palumbo K, Tomcik M, et al. Inhibition of AP-1 signaling abrogates TGF-βmediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum 2011.
26. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
27. Garcia-Gonzalez E, Selvi E, Balistreri E, et al. Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology (Oxford) 2009;48:1050-6.
28. Wei J, Bhattacharyya S, Tourtellotte WG, et al. Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy. Autoimmun Rev 2010;21:267-75.
29. Kulkarni AA, Thatcher TH, Olsen KC, et al. PPAR-γ ligands repress TGFβ-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis. PLoS One 2011;6:e15909.
30. Yamamoto T. Animal model of systemic sclerosis. J Dermatol 2010;37:26-41.
31. Wei J, Melichian D, Komura K, et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum 2011;63:1707-17.
32. Avouac J, Fürnrohr BG, Tomcik M, et al. Inactivation of the transcription factor STAT4 prevents inflammation-driven fibrosis in systemic sclerosis animal models. Arthritis Rheum 2010;30:800-9.
33. Reich N, Maurer B, Akhmetshina A, et al. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum 2010;62:280-90.
34. Venalis P, Maurer B, Akhmetshina A, et al. Lack of inhibitory effects of the antifibrotic drug imatinib on endothelial cell functions in vitro and in vivo. J Cell Mol Med 2009;13:4185-91.